Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G L Elfring

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Pharmacokinetics and Biopharmaceutics|October 1, 1978
Curve fitting and modeling in pharmacokinetics: a responseC M Metzler, G L Elfring
Lipids|January 1, 1977
Effects of colestipol hydrochloride and neomycin sulfate on cholesterol turnover in the ratW A Phillips, G L Elfring
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1981
The efficient use of NONLIN for unbalanced multiple dose dataG L Elfring, C M Metzler
Biometrics|September 1, 1973
Group sequential designs for clinical trialsG L Elfring, J R Schultz
Biometrics|June 1, 1973
Multiple-stage procedures for drug screeningJ R Schultz, F R Nichol, G L Elfring, et al.
Anti-Cancer Drugs|February 1, 1994
Phase I study of adozelesin (U-73,975) in patients with solid tumorsG J Shamdas, D S Alberts, M Modiano, et al.
The Oncologist|February 13, 2001
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standardL B Saltz, J Y Douillard, N Pirotta, et al.
Cancer Treatment Reports|June 1, 1982
Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeysJ P McGovren, J C Stewart, G L Elfring, et al.
Clinical Lung Cancer|January 17, 2004
Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trialM A Socinski, A B Sandler, L L Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancerM A Socinski, A B Sandler, L L Miller, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Pharmacokinetics and Biopharmaceutics|October 1, 1978
Curve fitting and modeling in pharmacokinetics: a responseC M Metzler, G L Elfring
Lipids|January 1, 1977
Effects of colestipol hydrochloride and neomycin sulfate on cholesterol turnover in the ratW A Phillips, G L Elfring
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1981
The efficient use of NONLIN for unbalanced multiple dose dataG L Elfring, C M Metzler
Biometrics|September 1, 1973
Group sequential designs for clinical trialsG L Elfring, J R Schultz
Biometrics|June 1, 1973
Multiple-stage procedures for drug screeningJ R Schultz, F R Nichol, G L Elfring, et al.
Anti-Cancer Drugs|February 1, 1994
Phase I study of adozelesin (U-73,975) in patients with solid tumorsG J Shamdas, D S Alberts, M Modiano, et al.
The Oncologist|February 13, 2001
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standardL B Saltz, J Y Douillard, N Pirotta, et al.
Cancer Treatment Reports|June 1, 1982
Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeysJ P McGovren, J C Stewart, G L Elfring, et al.
Clinical Lung Cancer|January 17, 2004
Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trialM A Socinski, A B Sandler, L L Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancerM A Socinski, A B Sandler, L L Miller, et al.
Pageof 2